Clinical Trial Update: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) [Phase 3]

View source ↗

Summary

Phase 3 trial of olezarsen in familial chylomicronemia syndrome has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• Olezarsen (olezarsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Familial Chylomicronemia Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2025-03-06